Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Loures – page 50

658 clinical trials in Loures, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Loures at a glance
658
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

658 trials in Loures

Open in trial search

Colorectal adenocarcinoma+1

Not recruiting

Study of Romiplostim Treatment for Chemotherapy-induced Low Blood Platelets in Adults with Gastrointestinal, Pancreatic, or Colorectal Cancer Receiving Oxaliplatin Chemotherapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

Colorectal cancer metastatic+1

Not recruiting

Study on Preventing Blood Clots with Tinzaparin in Patients with Metastatic Colorectal Cancer Starting First-Line Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Tinzaparin Sodium
  • Sponsor:Grupo Gallego De Investigacion En Tumores Digestivos

Oesophageal squamous cell carcinoma+2

Not recruiting

Study on Budesonide Tablets for Preventing Esophageal Narrowing in Adults After Cancer Tissue Removal

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Pulmonary arterial hypertension

Not recruiting

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Colorectal cancer metastatic

Not recruiting

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Small cell lung cancer limited stage

Not recruiting

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hypoparathyroidism

Not recruiting

Study on the Effectiveness and Safety of Eneboparatide, Calcitriol, and Calcium Carbonate for Patients with Chronic Hypoparathyroidism

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Alexion Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Loures

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, particularly exploring new therapies for HER2-positive and hormone receptor-positive variants. Studies include novel combinations of targeted therapies and immunotherapy approaches.

  • Advanced breast cancer therapies
  • HER2-positive treatment strategies
  • Non-small cell lung cancer interventions

Research includes evaluation of drugs like trastuzumab deruxtecan and combination therapies targeting specific cancer mutations.

02 Neurological Disorders

Comprehensive studies investigating treatments for multiple sclerosis and neurodegenerative conditions. Research focuses on both relapsing and progressive forms of MS, along with early-stage Alzheimer's disease.

  • Multiple sclerosis therapies
  • Alzheimer's disease treatments
  • Cognitive function studies

Trials evaluate medications like ocrelizumab and semaglutide for various neurological conditions.

03 Inflammatory Conditions

Advanced research into inflammatory bowel diseases, including studies on Crohn's Disease and Ulcerative Colitis. Trials evaluate novel therapeutic approaches and combination treatments.

  • Crohn's Disease management
  • Ulcerative Colitis treatments
  • Combination therapy approaches

Studies investigate medications such as risankizumab and ozanimod for long-term disease management.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.